Home > Oncology > ESMO 2021 > Basic Science & Translational Research > Gut microbiota as a potential predictive biomarker

Gut microbiota as a potential predictive biomarker

Presented By
Dr Kentaro Sawada, Kushiro Rosai Hospital, Japan
Conference
ESMO 2021
Trial
MONSTAR-SCREEN
The diversity of gut microbiota just before treatment with a checkpoint inhibitor is of predictive value for response and progression-free survival (PFS), first results of the Japanese MONSTAR-SCREEN trial suggest. In addition, sarcopenia in cancer patients appears to be associated with the composition of the gut microbiome. Immune checkpoint inhibitors (ICIs) have shown promising anti-tumour activity in a variety of cancer types, and gut microbiota have been shown to modulate efficacy of ICIs [1]. For example, Bifidobacterium longum, Dorea formicigenerans, and Enterococcus faecium are associated with good response of ICIs, whereas Prevotella histocola, and Bacteroidales are associated with poor response of ICIs. In addition, the diversity of the gut microbiome is regarded as predictive for favourable responses to ICIs. MONSTAR-SCREEN is a nationwide cancer genome-screening project that prospectively asse...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on